Esperion Therapeutics, Inc. (Esperion) will acquire Corstasis Therapeutics Inc. (Corstasis) through a merger, making Corstasis a wholly-owned subsidiary. The upfront cash consideration for the acquisition is $75,000,000, subject to customary adjustments. Corstasis equityholders are eligible for up to an additional $180,000,000 in milestone payments tied to regulatory approvals and commercial sales achievements. Equityholders will also receive low double-digit royalties on worldwide sales of Enbumyst and any follow-on products. The acquisition is expected to close in the second quarter of 2026. Esperion will finance the acquisition using existing credit facilities and royalty monetization of its Japanese royalties with funds managed by Athyrium Capital Management and HealthCare Royalty. Enbumyst (bumetanide nasal spray) is the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure (CHF), hepatic, and renal disease in adults, approved in September 2025. Corstasis is also advancing a sub-cutaneous pipeline, including a multidose pen injector, which could unlock additional market opportunities.